NewGenIvf Group Stock Scheduled to Reverse Split on Tuesday, September 1st (NASDAQ:NIVF)

Shares of NewGenIvf Group Limited (NASDAQ:NIVF) are going to reverse split on Tuesday, September 1st. The 1-3 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, August 31st.

NewGenIvf Group Stock Performance

NewGenIvf Group stock opened at $0.56 on Thursday. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.12 and a quick ratio of 2.98. NewGenIvf Group has a fifty-two week low of $0.45 and a fifty-two week high of $513.00. The stock’s fifty day moving average is $1.26 and its two-hundred day moving average is $4.56.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of NewGenIvf Group in a research note on Friday, July 24th. Wall Street Zen raised shares of NewGenIvf Group to a “hold” rating in a research note on Saturday, July 4th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Insider Activity

In related news, major shareholder Financial Lp Hrt bought 45,847 shares of NewGenIvf Group stock in a transaction that occurred on Friday, May 22nd. The shares were purchased at an average price of $2.97 per share, with a total value of $136,165.59. Following the purchase, the insider owned 37,295 shares in the company, valued at $110,766.15. This represents a -536.10% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 31.80% of the stock is owned by corporate insiders.

NewGenIvf Group Company Profile

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.